Form 4: Teladoc Health Exec Sells Shares for Tax Obligations

Kelly Bliss, President of U.S. Group Health at Teladoc Health, reported the vesting of equity awards and a subsequent sale of shares to cover tax withholding obligations.

Summary

• Kelly Bliss, President, U.S. Group Health at Teladoc Health, Inc. (TDOC), reported multiple transactions related to equity awards.
• On February 27, 2026, Bliss acquired a total of 51,340 shares of common stock through the conversion of various Restricted Stock Units (RSUs) and Performance Stock Units (PSUs).
• On February 27, 2026, Bliss was awarded 27,458 Performance Stock Units (PSUs) based on the issuer's 2025 financial results.
• On March 1, 2026, Bliss was awarded 181,661 Restricted Stock Units (RSUs).
• On March 2, 2026, Bliss sold 26,647 shares of Teladoc Health common stock at a price of $5.117 per share.
• The sale of shares was explicitly stated to cover tax withholding obligations arising from the vesting of performance stock unit and restricted stock unit awards.
• Following these transactions, Bliss directly beneficially owns 84,747 shares of common stock and holds various unvested derivative securities, including 19,435, 73,222, and 181,661 Restricted Stock Units, and 27,458 and 22,260 Performance Stock Units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It details routine executive compensation events, including the vesting of equity awards and a standard sale of shares to cover tax obligations, which does not alter the fundamental outlook for Teladoc Health.

Positives

• The executive received significant equity awards, including 27,458 Performance Stock Units based on 2025 financial results and 181,661 Restricted Stock Units, indicating continued compensation and alignment with company performance.
• The vesting of 51,340 shares from previously granted equity awards demonstrates the executive's continued long-term incentive compensation.

Negatives

• The sale of 26,647 shares, while for tax purposes, reduces the executive's direct common stock holdings by that amount.

Future Outlook

The filing details future vesting schedules for various equity awards, indicating ongoing long-term incentive compensation for the executive. Specifically, new Performance Stock Units (27,458) and Restricted Stock Units (181,661) will vest in installments, with initial vesting dates on March 1, 2026, and the first anniversary of their grant date, respectively, followed by eight substantially equal quarterly installments.

Industry Context

StockSavvy.ai notes that routine Form 4 filings, such as this one detailing executive equity award vesting and tax-related sales, are common across publicly traded companies. They reflect standard executive compensation practices and do not typically indicate broader industry trends or competitive shifts. The grant of new performance-based units suggests Teladoc Health continues to tie executive incentives to company performance metrics, a common practice in the healthcare technology sector.

Comparison to Industry Standards

• The structure of equity awards, including Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) with multi-year vesting schedules, aligns with common executive compensation practices observed in the technology and healthcare sectors.
• The sale of shares to cover tax withholding obligations upon vesting is a standard and expected practice for executives receiving equity compensation, similar to practices at companies like Amwell (AMWL) or Doximity (DOCS).
• The grant of performance-based units tied to "issuer's 2025 financial results" is a typical mechanism to align executive incentives with company performance, a strategy widely adopted by peers to drive shareholder value.

Related Party Transactions

• The transactions involve an executive (Kelly Bliss) and the company (Teladoc Health, Inc.), which are inherently related party dealings concerning executive compensation in the form of equity awards.

Stakeholder Impact

• Shareholders: The sale of shares for tax purposes is a routine event and is unlikely to have a significant direct impact on existing shareholders. The granting of new equity awards aligns executive incentives with shareholder interests.

Next Steps

• Remaining portions of the 41,853 restricted stock units (granted March 3, 2023) will vest in eight substantially equal quarterly installments after March 1, 2024.
• Remaining portions of the 58,300 restricted stock units (granted March 19, 2024) will vest in eight substantially equal quarterly installments beginning on June 1, 2025.
• Remaining portions of the 109,832 restricted stock units (granted March 1, 2025) will vest in eight substantially equal quarterly installments after March 1, 2026.
• Remaining portions of the 14,263 performance stock units (earned March 1, 2024) will vest in eight substantially equal quarterly installments after March 1, 2024.
• Remaining portions of the 27,458 performance stock units (awarded February 27, 2026) will vest in eight substantially equal quarterly installments after March 1, 2026.
• Remaining portions of the 27,458 performance stock units (earned March 1, 2026) will vest in eight substantially equal quarterly installments after March 1, 2026.
• Remaining portions of the 181,661 restricted stock units (granted March 1, 2026) will vest in eight substantially equal quarterly installments after the first anniversary of the grant date.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation events, including the vesting of equity awards and a subsequent sale of shares to cover tax obligations. These transactions are standard and do not provide new information that would fundamentally alter the investment thesis for Teladoc Health. Therefore, a 'hold' recommendation is appropriate as the filing does not present a compelling reason to buy or sell the stock based solely on this information.

Keywords

Teladoc Health, TDOC, Form 4, Insider Trading, Equity Awards, Restricted Stock Units, Performance Stock Units, Executive Compensation, Stock Sale, Tax Withholding